Evidence map›Paper›PMID 34315966›Full record

SynthesisScientific reports2021

Tranexamic acid in non-traumatic intracranial bleeding: a systematic review and meta-analysis.

Jean-Baptiste Bouillon-Minois, Carolyne Croizier, Julien S Baker, Bruno Pereira, Farès Moustafa, Justin Outrey, Jeannot Schmidt, Nicolas Peschanski, Frédéric Dutheil

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 6 pooled it
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 6 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Review
  8. Review
  9. Article
  10. Pharmacotherapy in SAH: Clinical Trial Lessons.CNS & neurological disorders drug targets · 2024
    Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Jean-Baptiste Bouillon-MinoisCNRS, LaPSCo, Physiological and Psychosocial Stress, CHU Clermont-Ferrand, Emergency Medicine, Université Clermont Auvergne, 63000, Clermont-Ferrand, France. jbb.bouillon@gmail.com.
Carolyne CroizierDepartment of Hematology and Cell Therapy, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France.
Julien S BakerCentre for Health and Exercise Science Research, Department of Sport, Physical Education and Health, Hong Kong Baptist University, Kowloon Tong, Hong Kong.
Bruno PereiraClinical Research and Innovation Direction, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France.
Farès MoustafaEmergency Department, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France.
Justin OutreyEmergency Department, CHU de Besançon, Besançon, France.
Jeannot SchmidtCNRS, LaPSCo, Physiological and Psychosocial Stress, CHU Clermont-Ferrand, Emergency Medicine, Université Clermont Auvergne, 63000, Clermont-Ferrand, France.
Nicolas PeschanskiEmergency Department & SAMU, University of Rennes Hospital, 35000, Rennes, France.
Frédéric DutheilCNRS, LaPSCo, Physiological and Psychosocial Stress, CHU Clermont-Ferrand, Occupational and Environmental Medicine, Université Clermont Auvergne, WittyFit, 63000, Clermont-Ferrand, France.
Centre Hospitalier Universitaire de Clermont-Ferrand · FRCentre National de la Recherche Scientifique · FRCentre Hospitalier Universitaire de Besançon · FRHong Kong Baptist University · HKUniversité Rennes 2 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-traumatic intracranial bleeding (NTIB), comprising subarachnoid hemorrhage (SAH) and intra-cranial bleeding (ICH) is a significant public health concern. Tranexamic acid (TXA) is a promising treatment with benefits yet to be fully demonstrated. We conducted a systematic review and meta-analysis on the impact of TXA on mortality in NTIB. We searched the PubMed, Cochrane Library, Google Scholar and ScienceDirect databases for studies reporting mortality data following the use of TXA in NTIB for comparisons with a control group. We computed random-effect meta-analysis on estimates of risk and sensitivity analyses. We computed meta-regression to examine the putative effects of the severity of NTIB, sociodemographic data (age, sex), and publication date. Among potentially 10,008 articles, we included 15 studies representing a total of 4883 patients: 2455 receiving TXA and 2428 controls; 1110 died (23%) during the follow-up. The meta-analysis demonstrated a potential of 22% decrease in mortality for patients treated by TXA (RR = 0.78, 95%CI 0.58-0.98, p = 0.002). Meta-regression did not demonstrate any influence of the severity of NTIB, age, sex, length of treatment or date of publication. Sensitivity analyses confirmed benefits of TXA on mortality. TXA appears to be a therapeutic option to reduce non-traumatic intracranial bleeding mortality, particularly in patients with SAH.

Indexed as

AdultAgedAntifibrinolytic AgentsCase-Control StudiesFemaleHumansIntracranial HemorrhagesMaleMiddle AgedTranexamic AcidYoung AdultAntifibrinolytic AgentsTranexamic Acid

Identifiers

PMID34315966
PMCPMC8316462
OpenAlexW3186234741

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.